Evidence map›Paper›PMID 32744131›Full record

ArticlemAbs

Affinity maturation of antibodies by combinatorial codon mutagenesis versus error-prone PCR.

Jan Fredrik Simons, Yoong Wearn Lim, Kyle P Carter, Ellen K Wagner, Nicholas Wayham, Adam S Adler, David S Johnson

Open access · goldAbstract readVideo-Audio Media
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. EngineeringMicroorganisms · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Progress toward improved understanding of antibody maturation.Current opinion in structural biology · 2021
    Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jan Fredrik SimonsGigaGen, Inc ., South San Francisco, CA, USA.
Yoong Wearn LimGigaGen, Inc ., South San Francisco, CA, USA.ORCID 0000-0002-8568-4901
Kyle P CarterGigaGen, Inc ., South San Francisco, CA, USA.
Ellen K WagnerGigaGen, Inc ., South San Francisco, CA, USA.
Nicholas WayhamGigaGen, Inc ., South San Francisco, CA, USA.
Adam S AdlerGigaGen, Inc ., South San Francisco, CA, USA.ORCID 0000-0001-9301-0037
David S JohnsonGigaGen, Inc ., South San Francisco, CA, USA.ORCID 0000-0002-9967-9812
GigaGen (United States) · US

Funding

Next-Generation Antibody Discovery and Development TechnologyR44CA187852 · NCI · GIGAGEN, INC. · PI JOHNSON, DAVID SCOTT · 2016 to 2018
$1.6M
NCI NIH HHS R44 CA187852
6 · The paper itself

Abstract

in vitroaffinity maturation of therapeutic monoclonal antibodies is commonly applied to achieve desired properties, such as improved binding kinetics and affinity. Currently there are no universally accepted protocols for generation of variegated antibody libraries or selection thereof. Here, we performed affinity maturation using a yeast-based single-chain variable fragment (scFv) expression system to compare two mutagenesis methods: random mutagenesis across the entire V(D)J region by error-prone PCR, and a novel combinatorial mutagenesis process limited to the complementarity-determining regions (CDRs). We applied both methods of mutagenesis to four human antibodies against well-known immuno-oncology target proteins. Detailed sequence analysis showed an even mutational distribution across the entire length of the scFv for the error-prone PCR method and an almost exclusive targeting of the CDRs for the combinatorial method. Though there were distinct mutagenesis profiles for each target antibody and mutagenesis method, we found that both methods improved scFv affinity with similar efficiency. When a subset of the affinity-matured antibodies was expressed as full-length immunoglobulin, the measured affinity constants were mostly comparable to those of the respective scFv, but the full-length antibodies were inferior to their scFv counterparts for one of the targets. Furthermore, we found that improved affinity for the full-length antibody did not always translate into enhanced binding to cell-surface expressed antigen or improved immune checkpoint blocking ability, suggesting that screening with full-length antibody or antigen-binding fragment formats might be advantageous and the subject of a future study.

Indexed as

MutagenesisSingle-Chain AntibodiesAntibody AffinityComplementarity Determining RegionsHumansPolymerase Chain ReactionComplementarity Determining RegionsSingle-Chain AntibodiesAffinity maturationmutagenesis libraryyeast scFv display

Identifiers

PMID32744131
PMCPMC7531523
OpenAlexW3046828715

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.